What is known and objective: With the increasing prevalence of diabetes, the physician-centred model is challenged to deliver holistic care in Asia. Diabetes may be managed effectively within a multidisciplinary collaborative care model; however, evidence on its effectiveness in Asian patients is lacking. Therefore, the primary objective was to evaluate the clinical outcomes of multidisciplinary collaborative care vs physician-centred care in diabetes. The secondary objectives were to evaluate humanistic and economic outcomes among the two types of care.
| WHAT IS KNOWN AND OBJECTIVE
The prevalence of diabetes is rising at an alarming rate, and Asia is especially vulnerable as it is home to more than 60% of world's population, with the majority living in China and India. 1 With the rising diabetes prevalence, the conventional care model commonly found in Asia, where physicians are the sole caregiver who attends to the needs of many patients, is challenged to deliver holistic care. 2 Primary care physicians voiced that time constraints due to increased patient load were a prominent barrier to providing more comprehensive care. 2 Hence, these physicians were only able to spend an average of 5 minutes with each patient during clinic visits. 3 A study has shown that face-to-face discussions between physicians and diabetic patients on blood glucose readings were only conducted in 40% of clinic visits. 3 The duration and the quality of the contact time were determined to be insufficient to address the needs of patients, especially those with multiple comorbidities and taking multiple medications. To overcome these challenges, a partnership among various diabetes experts which includes pharmacists, nurses and dietitians has been shown to provide well-rounded care that meets the needs of patients. 4 In the collaborative management of patients with diabetes, pharmacists, nurses and dietitians, for example, are able to optimize medications, provide motivational counselling on self-care practices and advise on nutrition therapy, respectively. 4 Today, the impact of this form of care in a much-challenged patient population in Asia is yet to be elucidated. In this population, treatment is often complicated by cultural beliefs, religious practices, polypharmacy, limited formulary and poor adherence to self-monitoring of blood glucose (SMBG). [5] [6] [7] Furthermore, evidence on its impact on quality of life and cost savings for this high-risk group of patients is not available.
Therefore, the primary objective of this study was to compare the clinical impact of multidisciplinary collaborative care to physiciancentred care in managing patients with diabetes. The secondary objectives were to evaluate patient-reported humanistic outcomes, as well as diabetes-related health service utilization rates and expenditures between the two types of care approaches. 
| METHODS

| Study design and setting
| Recruitment of study participants
High-risk patients aged ≥21 years with uncontrolled type 2 diabetes (defined as glycated haemoglobin [HbA1c] >7%), polypharmacy (defined as taking ≥five chronic medications) 9 and multiple comorbidities (defined as chronic conditions other than diabetes that are classified in the tenth revision of the International Classification of Diseases) 10 were included in this study. Patients with type 1 diabetes or those who were unable to communicate independently were excluded. Patients were approached and screened by trained research assistants, and eligible patients were invited to join the study.
| Study procedures and randomization
Upon signing the informed consent forms, patients were randomized into the intervention (multidisciplinary collaborative care) or control (usual care) arms. In the intervention arm, physicians referred their patients to the diabetes nurse educators or dietitians as needed, while clinical pharmacists followed up regularly with all patients every four to 6 weeks via face-to-face visits or phone calls, following an established protocol. 5, 11, 12 Each face-to-face session with the clinical pharmacists, diabetes nurse educators and dietitians lasted between 20 and 30 minutes ( Figure 1 ). All clinical pharmacists were boardcertified pharmacotherapy specialists. 13 Patients randomized into the control arm had no regular contact with clinical pharmacists. The randomization procedures were conducted by research assistants with an allocation ratio of 1:1 into the intervention or control arms, using a simple unrestricted randomization technique. 14 Audits on the randomization procedures were conducted at regular intervals throughout the study by study investigators.
| Data collection and outcome measures
The primary outcomes included surrogate endpoints, such as HbA1c, systolic blood pressure (SBP), low-density lipoprotein (LDL) and triglycerides (TG), and were collected from the electronic databases at baseline, 3 and 6 months. 
| Statistical analysis
Sample size was calculated using an estimate of a 0.7% difference in mean HbA1c change between the intervention and control arms. 21 After accounting for a 50% dropout rate, 165 patients were needed in each arm (two-sided, alpha=5%, power=80%). The baseline sociodemographic and medical characteristics such as age, gender, ethnicity, level of education, types of residence, employment and marital status, duration of living with diabetes, body mass index (BMI) and HbA1c between patients in the intervention and control arms and between patients who dropped out of the study and those who completed the study were examined using the chisquared test and Mann-Whitney U test, as appropriate. Using a linear mixed model, the changes in HbA1c and SBP between the two arms were analysed from baseline to 3 months and baseline to 6 months, whereas the changes in LDL, TG, PAID and DTSQ between the two arms were analysed from baseline to 6 months.
All univariate analyses were followed by multivariate analyses with study site as a random effect, study arm-by-time period as an interaction term, and sociodemographic and medical characteristics as covariates. Health service utilization rates and costs were analysed between the two arms using the Mann-Whitney U test.
The P-value for repeated analysis was multiplied as appropriate, and a two-tailed P<.05 was considered statistically significant. All intention-to-treat analyses were performed using linear mixed models. 22 These models which are also known as the likelihoodbased methods include all randomized patients in the analysis and allow for estimation of patients' outcomes after dropout. 23 All analyses were conducted using IBM SPSS Statistics for Windows version 22.0 (Armonk, NY, USA). 
| RESULTS
Of the 1540 patients approached, 599 (38.9%) declined participation due to work and personal commitments, 421 (27.3%) did not fit the inclusion criteria, and 109 (7.1%) refused to be part of the study. The remaining 411 (26.7%) who agreed to participate were randomized into the intervention (n=214) and control (n=197) had an average of four comorbidities, with the most commonly reported comorbidities including hypertension, dyslipidaemia, ischaemic heart disease and kidney disease. Overall, the two arms were comparable in all baseline parameters ( Table 1 ). The average number of chronic medications prescribed was 6.6±1.6. In addition, only 18.2%
(n=75) performed SMBG.
| Glycaemic control
Mean HbA1c at baseline was comparable between the intervention and control arms (I: 8.6%±1.5%, C: 8.5%±1.4%; P=.70) ( Figure 3A) .
From baseline to 6 months, the mean HbA1c in the control arm remained unchanged. However, in the intervention arm, the mean HbA1c decreased by 0.3% and 0.5% at 3 and 6 months, respectively.
Overall, an average HbA1c difference of 0.5% among the two arms was observed at 6 months (P=.04). Neither arms achieved HbA1c goal of <7% at 6 months. Based on our subanalysis, when the mean baseline HbA1c was ≥8.0%, a larger HbA1c reduction was observed in the intervention arm at 6 months (I: −0.8% vs C: −0.2%) ( Figure 3B ).
| Blood pressure and cholesterol control
Mean SBP at baseline was comparable between both arms (I: 
| Patient-reported outcomes
Average PAID scores at baseline were comparable for both arms 
| Diabetes-related health service utilization and expenditure
The average number of physician visits per patient over the 6-month period was two visits for the intervention arm and three visits for the control arm (P<.001). The average number of face-to-face visits and 0.3±0.7, C: 0.2±0.6; P=.12) was comparable between the two arms.
Overall, the proportion of physician workload, defined by the number of patient visits, was 30.7% in the intervention arm and 77.8% in the control arm.
The 6-month mean cost for direct outpatient diabetes-related care
was US$516.77 for the intervention arm and US$607.78 for the control arm (P<.001; Table 2 ). Medication costs were the biggest contributor to healthcare cost in both arms. Compared to the control arm, an average cost savings of US$91.01 per patient over 6 months was achieved by the intervention arm.
| DISCUSSION
Compared to usual care, a mean HbA1c reduction of up to 0.8% was observed in patients in the multidisciplinary collaborative care arm with poorer baseline control. Similar to a study conducted in the United States, patients with a mean baseline HbA1c of 8.8% in the collaborative care arm had a larger reduction in mean HbA1c as compared to usual care (I: −0.8%, C: −0.05%; P=.03). 24 Poor glucose control is often due to inappropriate drug usage and lack of close follow-up; hence, closer monitoring by clinical pharmacist provided timely drug optimization. 24 In addition, the clinical pharmacists in our study were trained to use the SIGN algorithm specifically designed for
Asian patients who refuse to use a glucose meter, 5, 11 and active insulin titration was still carried out despite low adherence rates of SMBG.
Due to these interventions of the clinical pharmacists, patients in the multidisciplinary collaborative care arm benefitted from glycaemic improvement as any degree of improvement in HbA1c would lower the risk of diabetes-related complications. 25 Furthermore, patients in the multidisciplinary collaborative care arm experienced reduced diabetes-related distress and greater satisfaction with their treatment. This care approach enables pharmacists, nurses and dietitians to spend adequate amounts of time providing individualized diabetes education and counselling. They are also able to improve patients' confidence and knowledge, and empowered patients also tend to achieve better quality of life and higher satisfaction towards treatment for diabetes. 26 In a 6-month study, 
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In addition, the inclusion of a multidisciplinary care team also lightened the physicians' workload. One study has found that the addition of regular visits with pharmacists that complement physician visits increases physician productivity. 27 Physicians were able to spend more time with other patients, who may be more acutely sick or require immediate attention, while the expanded role of the clinical pharmacists in counselling, monitoring and drug optimization led to improved overall quality of patient care. 28 The total diabetes-related outpatient gross cost incurred per patient for 6 months in our study was 15.0% less in multidisciplinary collaborative care than usual care. Similarly, one study demonstrated a 7.8%-21.9% decrease in total direct costs for patients with diabetes who received pharmacist consultation in an outpatient setting over a 2-year period. 29 Our cost savings (US$91.01 per patient) were comparable to a 6-month study in the United States, which found savings of US$84.00 per patient. 30 The cost savings observed in our study were attributed to the lower medication costs in patients managed by the multidisciplinary care team. When pharmacists are actively involved in patient care, studies have revealed cost savings as a result of closer therapeutic monitoring as well as substitution of brand name drugs to generic drugs. 31 On the contrary, medication costs may be higher in the usual care setting due to a lack of thorough medication use assessment and hence, patients who fail to reach recommended clinical targets may be switched to, or added, a more expensive drug unnecessarily.
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This study had several limitations. First, we were unable to assess long-term outcomes due to the short study duration. However, the positive trends in the clinical, humanistic and economic parameters observed at 6 months suggest similar trends over longer periods of time. Second, the dropout rate was much higher in the multidisciplinary collaborative care arm than the usual care arm because diabetes nurse educators, dietitians and clinical pharmacists were unable to provide patients with sickness notes to excuse their absence from work due to medical appointments. This study, however, was still sufficiently powered to detect the differences between the two arms. In addition, the dropout rate of the multidisciplinary collaborative care arm remained comparable to the dropout rate observed in the intervention arms of similar studies conducted in other countries (8.1%-59.5%). [33] [34] [35] Furthermore, the overall dropout rate of our study was consistent with other randomized controlled trials (19%-29%). 36, 37 Third, 38.9% of patients approached during recruitment declined participation due to work and personal commitment. This could also be compounded by a lack of familiarity with new health services including multidisciplinary collaborative care among these patients. However, the rate of patients refusing to participate in our study is consistent with other similar studies (27.3%-66.2%). [38] [39] [40] Fourth, our study only considered the direct T A B L E 2 Diabetes-related expenditure over 6-mo period outpatient medical costs from an institution's perspective. This finding served as the first-hand evidence in the economic evaluations of multidisciplinary collaborative care in Asia and may be enhanced with indirect cost estimations. Lastly, due to differences in patient population, study design, healthcare systems and practice privileges of healthcare professionals across studies, direct comparison with other studies is not possible. However, the control arm in our study served as a good comparison to illustrate the impact of the multidisciplinary collaborative care.
| WHAT IS NEW AND CONCLUSION
This was the first multicenter, randomized controlled study that il- 
